91 related articles for article (PubMed ID: 14769212)
21. Chemoenzymatic synthesis of HIV-1 gp41 glycopeptides: effects of glycosylation on the anti-HIV activity and alpha-helix bundle-forming ability of peptide C34.
Wang LX; Song H; Liu S; Lu H; Jiang S; Ni J; Li H
Chembiochem; 2005 Jun; 6(6):1068-74. PubMed ID: 15883971
[TBL] [Abstract][Full Text] [Related]
22. Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation.
Gallo SA; Wang W; Rawat SS; Jung G; Waring AJ; Cole AM; Lu H; Yan X; Daly NL; Craik DJ; Jiang S; Lehrer RI; Blumenthal R
J Biol Chem; 2006 Jul; 281(27):18787-92. PubMed ID: 16648135
[TBL] [Abstract][Full Text] [Related]
23. [Inhibition of HIV-1 mediated cell-cell fusion by saponin fraction from Psidium guajava leaf].
Mao QC; Zhou YC; Li RM; Hu YP; Liu SW; Li XJ
Zhong Yao Cai; 2010 Nov; 33(11):1751-4. PubMed ID: 21434438
[TBL] [Abstract][Full Text] [Related]
24. Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction.
Mo H; Konstantinidis AK; Stewart KD; Dekhtyar T; Ng T; Swift K; Matayoshi ED; Kati W; Kohlbrenner W; Molla A
Virology; 2004 Nov; 329(2):319-27. PubMed ID: 15518811
[TBL] [Abstract][Full Text] [Related]
25. Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41.
Liu S; Lu H; Zhao Q; He Y; Niu J; Debnath AK; Wu S; Jiang S
Biochim Biophys Acta; 2005 May; 1723(1-3):270-81. PubMed ID: 15823507
[TBL] [Abstract][Full Text] [Related]
26. Discovery of small molecule fusion inhibitors targeting HIV-1 gp41.
Zhou G; Chu S
Curr Pharm Des; 2013; 19(10):1818-26. PubMed ID: 23092284
[TBL] [Abstract][Full Text] [Related]
27. Role of envelope processing and gp41 membrane spanning domain in the formation of human immunodeficiency virus type 1 (HIV-1) fusion-competent envelope glycoprotein complex.
Welman M; Lemay G; Cohen EA
Virus Res; 2007 Mar; 124(1-2):103-12. PubMed ID: 17129629
[TBL] [Abstract][Full Text] [Related]
28. [Inhibitory effect of polysaccharides on the six-alpha-helix bundle formation of HIV gp41 protein].
Wen XY; Wu SY; Xu W; Lv L; Liu SW; Rao JJ; Zhang JJ; Wang GF; Wan SH; Wu SG
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Oct; 27(10):1498-500. PubMed ID: 17959523
[TBL] [Abstract][Full Text] [Related]
29. Functional and structural characterization of HIV-1 gp41 ectodomain regions in phospholipid membranes suggests that the fusion-active conformation is extended.
Korazim O; Sackett K; Shai Y
J Mol Biol; 2006 Dec; 364(5):1103-17. PubMed ID: 17045292
[TBL] [Abstract][Full Text] [Related]
30. [Design, synthesis and activity assessment of aryl-substituent benzyl acid targeting HIV gp41].
Wang H; Chen Z; Qiu J; Yu X; Xie Y; Liu S
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Feb; 33(2):221-4. PubMed ID: 23443776
[TBL] [Abstract][Full Text] [Related]
31. [Anti-HIV-1 effect of compound K3 from flower of Japanese pagoda tree in vitro].
Zhang GH; Zheng YT
Zhong Yao Cai; 2006 Apr; 29(4):355-8. PubMed ID: 16913492
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of water-soluble derivatives of chiral gossypol as HIV fusion inhibitors targeting gp41.
Yang J; Li LL; Li JR; Yang JX; Zhang F; Chen G; Yu R; Ouyang WJ; Wu SW
Bioorg Med Chem Lett; 2018 Jan; 28(1):49-52. PubMed ID: 29162455
[TBL] [Abstract][Full Text] [Related]
33. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
Gustchina E; Hummer G; Bewley CA; Clore GM
J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and biological evaluation of 3-substituted 2,5-dimethyl-N-(3-(1H-tetrazol-5-yl)phenyl)pyrroles as novel potential HIV-1 gp41 inhibitors.
He XY; Zou P; Qiu J; Hou L; Jiang S; Liu S; Xie L
Bioorg Med Chem; 2011 Nov; 19(22):6726-34. PubMed ID: 22014749
[TBL] [Abstract][Full Text] [Related]
35. Anti-HIV-1 Activity Prediction of Novel Gp41 Inhibitors Using Structure-Based Virtual Screening and Molecular Dynamics Simulation.
Sepehri S; Saghaie L; Fassihi A
Mol Inform; 2017 Mar; 36(3):. PubMed ID: 27730744
[TBL] [Abstract][Full Text] [Related]
36. Anti-HIV-1 activity of trichobitacin, a novel ribosome-inactivating protein.
Zheng YT; Ben KL; Jin SW
Acta Pharmacol Sin; 2000 Feb; 21(2):179-82. PubMed ID: 11263268
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the biological activities of human immunodeficiency virus 1 P24 and GP41 expressed in Spodoptera frugiperda cells by use of bac-to-bac system.
Joshua MN; Qi Y; Fu-Hua Y; Yong-Xiu H
Acta Virol; 2000; 44(3):125-30. PubMed ID: 11155353
[TBL] [Abstract][Full Text] [Related]
38. Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41.
Wang Y; Lu H; Zhu Q; Jiang S; Liao Y
Bioorg Med Chem Lett; 2010 Jan; 20(1):189-92. PubMed ID: 19932616
[TBL] [Abstract][Full Text] [Related]
39. Making strides in peptide-based therapeutics.
Guarracino DA; Arora PS
Chem Biol; 2009 Sep; 16(9):919-20. PubMed ID: 19778718
[TBL] [Abstract][Full Text] [Related]
40. [Study of the mechanism of caffeoyl glucopyranoses in inhibiting HIV-1 entry using pseudotyped virus system].
Xia CL; Mao QC; Li RM; Chen ZP; Jiang SB; Jiang ZH; Liu SW
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Apr; 30(4):720-3. PubMed ID: 20423834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
